Glycines role in neurological health and its potential calming effects could suggest some benefits for migraine sufferers
Hechter, and A
Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously
DSIP is under active research for potential application in: Individuals with insomnia or light, fragmented sleep Those with chronic stress or HPA axis dysfunction Athletes and biohackers seeking enhanced recovery People working night shifts or experiencing circadian misalignment Adults with low growth hormone output or reduced sleep efficiency Patients with PTSD or trauma-related sleep disruption (research ongoing) DSIP is not FDA-approved for any medical condition and should only be used in research settings under supervision
It is important to note that these strategies are not FDA approved to prevent, mitigate, treat or cure kidney stones and should not be confused as such
In addition, the use of pleiotropic medications is associated with better adherence, as patients often have trouble following instructions and taking multiple medications 101
